Jack Hutchinson1, Laure Marignol2. 1. Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity College Dublin, Dublin, Ireland. 2. Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity College Dublin, Dublin, Ireland marignl@tcd.ie.
Abstract
BACKGROUND/AIM: Statins are cholesterol- lowering drugs that have been shown to possess anti-tumour properties. Observational studies have shown that 3-hydroxy-3-methlyglutaryl coenzyme A reductase inhibitor (statin) use may be associated with reduced prostate cancer risk. Preclinical studies suggest that statins possess anticancer and radiosensitising properties. This review aims to determine the impact of statin use in the efficacy of radiation therapy and the therapeutic window in prostate cancer. MATERIALS AND METHODS: The scientific databases PubMed, Science Direct, EMBASE, Cochrane Collaboration, and Google Scholar were searched for articles identifying statin use in histologically confirmed prostate cancer treated with external beam radiation therapy. RESULTS: Improvement was observed in freedom from biochemical failure (91% vs. 79%), relapse free survival (72% vs. 69%), distant metastasis free survival (96% vs. 94%), and prostate-specific antigen (PSA) relapse free survival (89% vs. 83%) with statin use, however this did not translate into an overall survival benefit for patients. Conflicting data concerning clinical outcomes reduce the integrity of these findings. The literature supports the radiosensitising properties of statins and their potential antitumor effects in prostate cancer. CONCLUSION: Statin use in prostate cancer presents many obstacles yet to be overcome, which warrant attention prior to the routine implementation of statins in treatment regimes. However, there is evidence to support their beneficial use. Copyright
BACKGROUND/AIM: Statins are cholesterol- lowering drugs that have been shown to possess anti-tumour properties. Observational studies have shown that 3-hydroxy-3-methlyglutaryl coenzyme A reductase inhibitor (statin) use may be associated with reduced prostate cancer risk. Preclinical studies suggest that statins possess anticancer and radiosensitising properties. This review aims to determine the impact of statin use in the efficacy of radiation therapy and the therapeutic window in prostate cancer. MATERIALS AND METHODS: The scientific databases PubMed, Science Direct, EMBASE, Cochrane Collaboration, and Google Scholar were searched for articles identifying statin use in histologically confirmed prostate cancer treated with external beam radiation therapy. RESULTS: Improvement was observed in freedom from biochemical failure (91% vs. 79%), relapse free survival (72% vs. 69%), distant metastasis free survival (96% vs. 94%), and prostate-specific antigen (PSA) relapse free survival (89% vs. 83%) with statin use, however this did not translate into an overall survival benefit for patients. Conflicting data concerning clinical outcomes reduce the integrity of these findings. The literature supports the radiosensitising properties of statins and their potential antitumor effects in prostate cancer. CONCLUSION:Statin use in prostate cancer presents many obstacles yet to be overcome, which warrant attention prior to the routine implementation of statins in treatment regimes. However, there is evidence to support their beneficial use. Copyright
Authors: Ke Li; Jie Si-Tu; Jianguang Qiu; Li Lu; Yunhua Mao; Hua Zeng; Mingkun Chen; Caiyong Lai; Heng-Jui Chang; Dejuan Wang Journal: Cancer Manag Res Date: 2019-02-04 Impact factor: 3.989
Authors: Natalia Ricco; Amy Flor; Don Wolfgeher; Elena V Efimova; Aishwarya Ramamurthy; Oliver K Appelbe; Jacqueline Brinkman; Andrew W Truman; Michael T Spiotto; Stephen J Kron Journal: Mol Oncol Date: 2019-07-26 Impact factor: 6.603
Authors: Hisham F Bahmad; Timothy Demus; Maya M Moubarak; Darine Daher; Juan Carlos Alvarez Moreno; Francesca Polit; Olga Lopez; Ali Merhe; Wassim Abou-Kheir; Alan M Nieder; Robert Poppiti; Yumna Omarzai Journal: Med Sci (Basel) Date: 2022-02-18
Authors: Kevin Kaulanjan; Danny Lavigne; Fred Saad; Pierre I Karakiewicz; Rocco Simone Flammia; Luis Alex Kluth; Philipp Mandel; Felix K-H Chun; Daniel Taussky; Benedikt Hoeh Journal: Cancers (Basel) Date: 2022-07-24 Impact factor: 6.575
Authors: Beste Turanli; Morten Grøtli; Jan Boren; Jens Nielsen; Mathias Uhlen; Kazim Y Arga; Adil Mardinoglu Journal: Front Physiol Date: 2018-05-15 Impact factor: 4.566
Authors: Miguel R Ferreira; Caroline J Sands; Jia V Li; Jervoise N Andreyev; Elena Chekmeneva; Sarah Gulliford; Julian Marchesi; Matthew R Lewis; David P Dearnaley Journal: Int J Radiat Oncol Biol Phys Date: 2021-08-02 Impact factor: 7.038